Background. Nephrologists need to better understand the impact of their decisions about long-term treatment strategies. Healthcare planning requires the anticipation of demand. Indicators from ESRD registries are especially difficult to interpret when the underlying dynamic process is not well understood. Therefore, we have developed a statistical tool to study the course of incident ESRD patient cohorts over time and to quantify, by simulations, the impact of various expected changes or new strategies. Methods. Based on the data from 67 258 ESRD adult patients, we first estimated transition rates between 10 different modalities of treatment ('compartments') with a multistate model. In a second step, we predicted the number of patients in each compartment at each time point for a cohort of 1000 patients for 180 months after the onset of renal replacement therapy (RRT). We tested two scenarios to illustrate the possibility of simulating policy changes. Results. Increased use of non-assisted automated peritoneal dialysis (PD) (from 7.7 to 19.2% at RRT onset) will not substantially influence the proportion of total RRT time in PD for patients aged 18-44 without diabetes. Improving access to kidney transplants from cadaveric donors for patients aged 45-69 with diabetes will increase the 15-year restricted mean lifetime by 5 months and the time spent with a functioning graft (34 versus 23%).
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Conclusions.
A model based on patients' treatment trajectories can improve the description and understanding of RRT as a dynamic phenomenon. Its use for simulation may help professionals and decision-makers to optimize renal organization and care.
I N T RO D U C T I O N
End-stage renal disease (ESRD) is a chronic state that may last many years before death. During this time, patients may receive various modalities of renal replacement therapy (RRT), including in-centre haemodialysis (HD), out-of-centre HD, continuous ambulatory peritoneal dialysis (PD), automated PD, renal transplantation from a living donor or from a deceased donor etc. Among the many factors related to treatment choice are clinical condition (such as frailty and associated comorbidities), patient preference, health professionals' experience or beliefs and existing renal-care supply (e.g. availability of renal grafts, self-care HD units, financial aspects) [1] [2] [3] [4] [5] [6] [7] [8] .
Although only a few randomized trials have compared specific RRT modalities, many observational studies have done so, e.g. comparing HD versus PD or dialysis versus renal transplantation [9] [10] [11] [12] [13] [14] [15] [16] [17] . Their results are not consistent, unsurprisingly, given that indication and selection bias cannot be completely controlled in such observational studies [18] . We therefore lack persuasive data about treatment outcomes, especially treatment courses combining various modalities. Standard approaches, such as the Cox proportional hazards model, may not be appropriate for comparing strategies with transfers between treatment modalities. More complex approaches, such as multistate models, even if they do not totally resolve indication bias, might well be more appropriate since they allow simulations and consider various treatments, outcomes (called states or compartments) and transitions.
ESRD patients require thorough and balanced information when they choose an RRT modality [19, 20] . Moreover, patients treatments may change during the course of their disease. These changes must be anticipated. Accordingly, information is needed about global long-term strategies that combine various complementary modalities. Similarly, healthcare planning requires anticipation of the necessary or available supply of these different modalities. Thus, our partners in the Ministry of Health and the health insurance funds also require information.
ESRD registries provide numerous essential indicators about RRT, such as point prevalence rates and patient counts by treatment modality [21, 22] . Nonetheless, these indicators are especially difficult to interpret when the underlying dynamic process is not well understood. Tools are necessary to assist both individual and public health decision-making and to answer various questions: How should renal-care supply be organized in the future? What strategies should be developed for which patient groups? What is the likely impact of various expected changes or new strategies?
To obtain this necessary dynamic vision of patient trajectories through RRT modalities, we are developing a statistical tool to simulate outcomes of an incident ESRD patient cohort and illustrate the course of their RRT over time. Our second aim is to simulate potential strategies, such as increasing the incidence of patients on PD or increasing access to transplantation to examine how these trends would change the distribution of patients through RRT modalities for 15 years after dialysis initiation.
M E T H O D S

Population
The Renal Epidemiology and Information Network (Rein) registry includes all ESRD patients on RRT-either dialysis or transplantation-treated in France. The details of its organizational principles and quality control are described elsewhere [23] . The registry began in 2002 and grew progressively to include the entire country. At the start of the registry in a region, all ( prevalent) dialysis patients in that region are registered. Patients with preemptive grafts and those living with a functioning graft are identified from the transplant database, which began in all regions in 1959 [24] . This study included all adult patients who received at least one RRT treatment between 2002 and 2010 in the regions for which the information system allows the linkage of dialysis treatments and transplantations, i.e. 19 regions corresponding to ∼71% of the French population. For patients for whom ESRD onset occurred after the region's inclusion in the database (i.e. incident patients), each patient's follow-up began on the first day of treatment. For patients whose ESRD onset preceded the region's inclusion in the database ( prevalent patients), followup started on the day of the region's inclusion (late entries, left truncation). The date of first RRT is known for each patient. Each patient was then followed until death or the study end point on 31 December 2010 (right truncation).
Basis of the model
The study considers seven types of events reported to the registry on occurrence: (i) RRT initiation, (ii) changes in the type of dialysis, (iii) renal transplantation, (iv) renal graft failure, (v) death, (vi) recovery of renal function and (vii) loss to follow-up (when patients move to a region or a country that does not participate in the registry). Ten modalities of treatment were defined: nurse-assisted automated PD (A-APD), non-assisted automated PD (nA-APD), nurse-assisted continuous ambulatory PD (A-CAPD), non-assisted continuous ambulatory PD (nA-CAPD), haemodialysis in a hospitalbased in-centre unit (CHD), haemodialysis in a medical satellite unit (MUHD), haemodialysis in a self-care or nurse-assisted satellite unit (AHD), haemodialysis at home (HHD), renal graft from a cadaveric donor (CRT) and renal graft from a living donor (LDRT).
We defined the treatment course of a patient as the successive passage between different treatment modalities at various times, and the time spent in each modality, until death or study end point. Our model is based on the transitions between modalities and the volume of patients in each modality at each time point. Because the exact date of each event is known, the length of time in a given state and the time, since RRT began for each transition can be calculated, and we can apply a continuous-time approach. A simplified version of the model (considering only three treatment modalities) is described in the supplementary files (see Supplementary Figure S3 ).
Our estimates were performed in six groups, stratified for age at ESRD onset: , , [70 years and over] and diabetes (comorbidity present or absent at RRT initiation).
Statistical methods
All the treatment courses were split into 1-month periods. To take into account treatment changes that could occur within a month, each month was again split to assess the patient's exact contribution to the given modality.
In a first step, we estimated the parameters (transition rates between the 10 modalities and between each of these modalities and death) with a multistate model [25, 26] . We considered each modality separately for each age and diabetes status, estimating the transition rates from this modality to the others and to death. These estimations resulted from maximizing a Poisson likelihood based on the number of patientmonths at risk and taking competing risks [27] into account (the possibility of transition into another compartment). We assumed that transition rates from one state to another do not depend on past transitions. The parameters of the model were estimated by using the first 180 months of follow-up (15 years). The transition rates were presumed constant within seven time intervals: [0-6] months, [6] [7] [8] [9] [10] [11] [12] months, [12] [13] [14] [15] [16] [17] [18] months, [18] [19] [20] [21] [22] [23] [24] months, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] months, 
In a second step, we predicted the mean volume of each compartment at each time point for a cohort of 1000 patients during the 180 months after RRT began. The predicted changes in compartment volumes (i.e. in the number of patients in each compartment) between time t and time t + 1 were estimated by resolving a system of differential equations (continuous-time deterministic structural model). We simulated the outcome of the cohort, based on the transition rate estimates in the first step and the initial distribution of the patients in the various modalities observed in REIN for each given age group and diabetes status. To check the validity of our model, we split our data set into two groups. In the first, we estimated our parameters. In the second, we compared the observed distribution of the patients in the various treatment modalities according to time since first RRT and the predicted distribution based on the estimation in the first group (see Supplementary Figure S2 ).
Representation of the results
The evolution of the simulated cohort is showed graphically by plotting aggregated patient distribution in the different compartments. The distribution in the death compartment was obtained from the estimator of actuarial survival. Distribution in the various other treatment compartments was based on the proportions observed for living patients.
The 15-year restricted mean lifetime for one patient was calculated considering the total months alive during the period for each simulation. Each simulation is conducted for a total of 180 months × 1000 patients = 180 000 months. Only the sum of the months alive are considered and then divided by 1000 to obtain the mean for one patient.
The feasibility of each scenario was approached by the number of transitions between RRT modalities ( per 1000 patients) during the period. The role of each treatment modality was summarized by the mean time spent in each modality.
Stimulation of new strategies
We were able to simulate new strategies by changing some transition rates or the initial distribution of patients in the various treatment modalities. Each scenario was then compared with the unchanged baseline scenario, for a 15-year restricted mean lifetime, the number of transitions between RRT modalities ( per 1000 patients) and mean time spent in each modality.
Two scenarios were tested to illustrate the possibility of simulating policy or population changes. The first scenario tested an increased use of non-assisted automated PD in patients aged 18-44 without diabetes. Because PD is a modality that is chosen mainly at RRT onset, this simulation successively applied an initial increase in the distribution of non-assisted automated PD from 7.7% (current practice) to 11.5, 15.4 and 19.2% and the percentage of in-centre HD decreased correspondingly. The transition rates between the compartments were left unchanged.
The second scenario tested improving access to kidney transplants from cadaveric donors for patients aged 45-69 with diabetes: this change implies more renal grafts available and a shorter time spent on the waiting list. This simulation multiplied the transition rates from all dialysis compartments by 2 and by 3 during the first 24 months. The initial treatment distribution was unchanged.
Sensitivity analyses
Increased transfers in a given compartment induced by envisioning some future scenarios could affect the behaviour of that compartment. If the increase concerns patients with 
characteristics similar to those of the patients currently transferred into that compartment, we can suppose that the compartment behaviour will remain stable. But if the increase is based on new indications, transition rates will change. To simulate new behaviour, we performed sensitivity analysis on out-transfers by envisioning different transition rates. In our
Simulated distribution of the patients in the various treatment modalities according to time since first RRT (in months), by age and diabetes status at RRT initiation.
O R I G I N A L A R T I C L E
M o d e l l i n g t h e R R T t r e a t m e n t c o u r s e second example, because increasing transplantation in patients aged 45-69 with diabetes might well lead to more deaths after transplantation, we performed a sensitivity analysis, increasing the transition rates from the compartment 'renal transplantation with cadaveric donor' to the compartment 'death' starting from the current one and then increasing it progressively until reaching the observed value of the transfer rate from the 'in-centre HD' compartment to the 'death' compartment.
R E S U LT S
Outcomes of 67 258 adult patients, registered in the French REIN registry, were used for this study. At inclusion, 33 271 were incident (ESRD onset date after registry start) and 33 987 prevalent patients (ESRD onset before inclusion in the registry). Table 1 summarizes the characteristics of both populations. As expected, prevalent patients are younger and more often treated with a renal graft. Patient distribution in the 11 different compartments-each treatment modality and deathaccording to time since first RRT (in months) differed according to age at RRT initiation and diabetes status (see Supplementary Figure S1 ). Figure 1 shows the simulated distribution of 1000 patients in these various compartments according to time since first RRT (in months), again, by age at RRT initiation and diabetes status. As expected, mortality increased with age and diabetes ( Table 2 ). The role of transplantation decreased with age and with diabetes, a change mirrored by the increased role of incentre HD. In all groups, PD accounted for only a small portion of the total time spent in RRT (Table 3) .
Of the patients younger than 45 years and without diabetes, 15.6% started with PD and 11.2% with a preemptive graft ( Table 2) . After 2 years, 47.5% of the patients were living with a renal graft. Fifteen years after RRT onset, overall 67.9% were still alive and had a renal graft, and 18.8% had died. The 15-year restricted mean lifetime was 161.9 months (of a possible maximum of 180 months) ( Table 3 ). Over the 15-year period, PD accounted for only 2.7% of the total RRT time, whereas transplantation accounted for 69.9%.
Of the younger patients with diabetes, 8.7% started with PD and 16.5% with a preemptive graft ( Table 2) . After 2 years, 42.9% of the patients were living with a renal graft. Fifteen years after RRT onset, only 37.1% were still alive and had a renal graft, and 48% were dead. The 15-year restricted mean lifetime was 130.8 months (Table 3) . During the 15-year period, PD accounted for only 2.3% of the total RRT time and transplantation for 60.3%. 11 .6% of the patients started with PD and 6.3% with a preemptive graft ( Table 2) . After 2 years, only 26.1% of the patients were living with a renal graft. Fifteen years after RRT onset, only 29.6% were still alive with a renal graft, and 62.2% had died. The 15-year restricted mean lifetime was 110.4 months (Table 3) . Over the 15-year period, PD accounted for only 3.4% of the RRT time and transplantation for 51.6%.
Of those aged 45-69 with diabetes, 9.9% started with PD and 1.5% with a preemptive graft ( Table 2) . After 2 years, only 7.9% of the patients were living with a renal graft. Fifteen years after RRT onset, 87% were dead. The 15-year restricted mean lifetime was 75.2 months, less than half the potential 180 months (Table 3) . Over the 15-year period, PD accounted for only 4.5% of the RRT time and transplantation for 23.6%.
Of those older than 70 years without diabetes, 14.6% started with PD ( Table 2) . After 2 years, only 6.8% were still on PD. Fifteen years after RRT onset, 97.7% had died. The 15-year restricted mean lifetime was 45.2 months (Table 3) . Over the 15-year period, PD accounted for 9.3% of the RRT time.
Of those in the oldest group who also had diabetes, 13.8% started with PD (Table 2) . After 2 years, only 6.3% of the patients were still on PD. Fifteen years after RRT began, 99.2% were dead. The 15-year restricted mean lifetime was 39.6 months (Table 3) . PD accounted for 9.8% of the RRT time over the 15-year period.
Two scenarios were tested to illustrate the possibility of simulating policy or population changes. The first scenario tested an increased use of non-assisted automated PD in patients aged 18-44 without diabetes. Because PD is a modality that is nearly always chosen only at RRT onset, this simulation successively applied an initial increase in the distribution of non-assisted automated PD from 7.7 to 11.5, 15.4 and 19.2%, and the percentage of in-centre HD decreased correspondingly. The transition rates between the compartments Based on a simulation covering a total of 180 months, impact on the 15-year restricted mean lifetime (months) and the total distribution of the various treatment modalities (column percentage).
F I G U R E 2 : Scenario 1: increasing use of non-assisted automated PD in patients of 18-44 years without diabetes. Impact on the distribution of patients in the different compartments from RRT initiation through the 180-month simulation period. The large white arrow points out the nA-APD compartment.
were left unchanged. Table 4 and Figure 2 present the result of this scenario, compared with the unchanged basic scenario. As shown, even such a major change in medical practice will not have an important impact on PD's proportion of total RRT time in young patients, because of the high transition rate to transplantation. Multiplying the initial percentage of patients starting with non-assisted automated PD by 2.5 will increase the total time spent in this modality by only 1.3%, i.e. 2 months, on average, for a restricted mean lifetime of 162 months. The second scenario tested improving access to kidney transplants from cadaveric donors for patients 45-69 years with diabetes: this change would imply greater availability of renal grafts and a shorter time spent on the waiting list. This simulation multiplied the transition rates from all dialysis compartments by 2 and by 3 during the first 24 months. The initial treatment distribution was unchanged. Because increasing transplantation in this group at potential risk could increase the risk of death, we performed a sensitivity analysis, increasing the transition rates from the compartment 'renal transplantation with cadaveric donor' to the compartment 'death' to the level observed from the compartment of incentre HD (extreme scenario). The results of this scenario and the sensitivity analysis are presented in Table 5 and Figure 3 . As expected, increasing the renal transplantation rate had a major impact on the number of transplantations performed, on the 15-year restricted mean lifetime and on the proportion of transplantation in the total RRT time. Increasing the risk of death from this compartment slightly reduced the impact of this strategy. Renal graft living donor 0.9 0.9 0.9 0.8 0.8
Impact on the 15-year restricted mean lifetime (months), the total number of renal transplantations performed and the total distribution of the various treatment modalities (column percentage) during the 180-month simulation period.
a Because increasing transplantation in this group might well lead to more deaths after transplantation, we performed a sensitivity analysis, increasing the transition rates from the compartment 'renal transplantation with cadaveric donor' to the compartment 'death' starting from the current one to the observed value of the transfer rate from the 'in-centre HD' compartment to the 'death' compartment.
D I S C U S S I O N
The high burden of ESRD has led many registries to develop tools to predict numbers of RRT patients at different points in the future. These tools can be divided into two categories. The first comprises multistate transition models, either deterministic or probabilistic. Their calculations are based on the observation of transitions between three treatment states-HD, PD and transplantation-and one absorbing state-death [28] [29] [30] [31] .
One study also included status on renal transplantation waiting list registration [29] . This type of study starts with the current number of prevalent patients and an estimation of future incident patients. These tools are useful for predicting future demand. They can also be used to simulate various scenarios of trends or changes in techniques or populations, such as more grafts [30] , increasing ESRD incidence [29, 31] , an increase in the percentage of patients with diabetes [29, 31] , better survival [29, 31] or different balances between HD and PD [29] . The second category of model uses historical data from time-series for forecasting [32] . They allow the number of ESRD patients in the future to be estimated, but they require long periods of historical data and cannot be used for simulations. Models have also been developed to provide cost-effectiveness analyses for ESRD. Some use multistate transition models [30, [33] [34] [35] [36] to simulate the use of more preemptive grafts [36] , more transplants from living donors [34] or increasing use of PD [33, 35] . Some are based on individual simulations of a cohort of incident patients and generate random patient profiles and medical histories for each patient [25] .
Because most of these models aimed to predict future prevalence counts, they have simulated prevalent patient cohorts mixed with incoming new patients on a calendar time axis. The vision of the underlying process is less clear than in our model, where the time axis is time since RRT began. In France, at least three treatment states are insufficient to illustrate the various therapies available. For this reason, our model includes 10 different treatments. Further compartments may be added in the future to take the development of new strategies into consideration, such as daily home HD, or out-centre dialysis supervised by telemedicine.
Some of the previous tools did take age and diabetes status into account but presented their final results as a whole for the entire population. We chose to stratify our cohort because, as our results illustrate, the course of the cohort differs substantially from one group to another, and future trend scenarios are also likely to vary in their effects according to age and diabetes status. It also improves the clarity of the results. But the main reason for choosing a stratification approach is that it allows the simulation of different scenarios according to the patients' age and diabetes. Healthcare planners, for example, are more likely to want to simulate more renal transplantations or more autonomous modalities in younger patients, and more assisted modalities among elderly patients. Our model makes it possible to differentiate scenarios according to the patient characteristics.
The strength of our model is that it allows a simulation of the treatment course of the patients in the context of various strategies and the quantification of the impact of various changes. Previously published models have not described current practices graphically nor did they illustrate the underlying dynamic phenomena. We think that the visual output we propose is a strong point of this paper, since it provides a simple description of a complex dynamic process.
The principal limitation of our model is that the transition rates are estimated from current practices and only at the national level. Past analyses suggest that substantial heterogeneity exists from one region to another or even from one centre to another. Moreover, increasing transfers in some F I G U R E 3 : Scenario 2: improving access to renal transplantation from a cadaveric donor graft for patients aged 45-69 with diabetes. Impact on the distribution of patients in the different compartments from RRT initiation through the 180-month simulation period. The large white arrow points out the CRT compartment.
compartments may change the global behaviour of this compartment and modify the transition rates toward other compartments. We conducted some sensitivity analysis to simulate some such resulting changes in transition rates, but the 'true' future behaviour is not known. The sensitivity analysis was based upon expert opinion.
A second limitation of our model was to consider, for technical reasons, that the rates were constant within seven separate time intervals. The initial description of our data showed that this simplification is acceptable, because most transitions occurred in the first 3 years (data not shown). We chose to use age and diabetes to characterize our patients, but introducing other risk factors for estimating particular transition rates would be likely to improve this tool.
In conclusion, a model based on patient treatment trajectories can usefully improve descriptions and understanding of the dynamic phenomenon of RRT. It should help nephrologists and patients as well as the Ministry of Health and the health insurance funds to optimize the organization of renal care and public health decision-making. It may also be a tool to facilitate evidence-based public health decisions by evaluating the performance of the organization of renal care, before and after modification, under different useful configurations and over long periods of time. Such a tool might also help to evaluate the benefit of various strategies. As many factors are related to treatment choice and in view of the lack of randomized clinical trials, simulations may be a way to promote translational research in public health and clinical medicine.
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